Sorry, you need to enable JavaScript to visit this website.

Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)

July 2, 2019

On June 27, 2019, Pfizer received FDA approval for ZIRABEV™ (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab). The FDA approval was based on review of a comprehensive data package which demonstrated biosimilarity of ZIRABEV to the reference product.

Please see the full press release via the link below for further details. For medical information, please call Pfizer at 1-800-438-1985